Post-translational modifications differentially affect IgG1 conformation and receptor binding.
about
Fc glycans of therapeutic antibodies as critical quality attributesMass spectrometry-based methods to study protein architecture and dynamicsA dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered Pichia pastorisIn vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activityOxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodiesInvestigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurementsMass spectrometric approaches to study protein structure and interactions in lyophilized powders.The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studiesAdvanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical productsHigh-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus.The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases.Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia.Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.High throughput quantification of N-glycans using one-pot sialic acid modification and matrix assisted laser desorption ionization time-of-flight mass spectrometryResolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approachesAleuria Aurantia Lectin (AAL)-reactive immunoglobulin G rapidly appears in sera of animals following antigen exposureOxidation of the alarmin IL-33 regulates ST2-dependent inflammation.Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometryAdvances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeuticsMulti-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues.Sialic Acid Derivatization for the Rapid Subclass- and Sialic Acid Linkage-Specific MALDI-TOF-MS Analysis of IgG Fc-Glycopeptides.The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.Production of α2,6-sialylated IgG1 in CHO cellsTime-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response.Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks.Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgGMass spectrometry for the biophysical characterization of therapeutic monoclonal antibodiesBspK, a Serine Protease from the Predatory Bacterium Bdellovibrio bacteriovorus with Utility for Analysis of Therapeutic Antibodies.Unraveling the dynamics of protein interactions with quantitative mass spectrometry.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis.The impact of mass spectrometry on the study of intact antibodies: from post-translational modifications to structural analysis.Oxidation of therapeutic proteins and peptides: structural and biological consequences.Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry.
P2860
Q26799266-EFFA2ABB-F35A-46ED-BF56-299CA409ED3DQ26827145-B00E0152-9D03-4E6B-8E99-FF3E8494AD81Q28534600-F2C3845C-AA8F-45FA-8BAF-7D5DB72F46A0Q28547176-E4EAB6A3-E183-43A1-AF41-E5381912B5D0Q28821982-E34962C8-A6A1-4758-B8D4-B7106DA08EEEQ30354666-E1712333-ED26-46ED-ACBF-FCA7FABB775EQ30374347-101035DA-9629-4A48-AED7-BE63929A89DCQ30401825-6415AD1C-8E90-40B7-934D-B3D74368C446Q30402317-0CC388A8-87EF-4003-BB91-92272390A63BQ30675226-50A2430E-3C06-475D-902C-AE4A2492DE3FQ31154829-08F8D4F8-41D6-49C4-9FA4-2792D7F15F9DQ33430624-D6507ADE-9B3A-4134-AB8C-8D22FC1395C9Q33431066-0B0AC0BC-76BC-4B0E-93D5-D06F0A044CA0Q33551688-518B52D9-F5FC-4A2B-ACDC-486D501181E1Q33619621-F2AF798D-F2D9-48E2-82F7-A3E82DD3E16FQ33641917-805BA3A3-29F2-4B87-8F8E-BF7E7F30DC9DQ34424997-D62836D2-8361-458A-BAAD-181CD4CE456CQ34493943-2EB7FD94-27D7-48DE-B5DD-2ED28FEEF522Q34884133-4E57D940-8343-401B-90EE-9C35D0E9500DQ35223810-6453879C-5B6F-4E92-A0DD-DDBA53C36ED4Q35866472-246B3E49-C883-4E39-B1DF-1531EA0AC7C4Q35874451-C66A1686-5576-4727-AC94-211693929967Q36164367-F5AD7F24-49EC-48F5-B651-3F7619DD6361Q36213158-43B34DD2-63B4-4F32-8341-5C838AA2BBFAQ36213182-D3F4BC5A-117A-4612-87DC-0E5C1BF2225EQ36213335-1CAF9D0E-CCF3-4583-BF70-73820A5D176BQ36239584-152BC66F-AE80-4D41-BC44-527126525CBCQ36637360-C8351263-855F-4F13-8DAD-BD0870A2A29BQ36836949-7B46195D-2650-4364-A96A-975D4D8A169BQ37022207-803ACA12-5F21-417B-B82A-741EF1556E16Q37461186-634A24AD-D9B6-4BB8-B8DC-41E608741BDBQ37484223-88006425-88A9-4C02-AD18-31B01A130AD3Q37567087-A19C8D6A-09EC-4275-A105-26827112EE49Q37620742-67F40983-F88B-4BCD-93C1-A65C3133B67BQ37857842-E6954E23-7F1E-42A4-8FFF-C382F62A6039Q37999739-45C67520-1BB8-4A3B-BBAE-C773EB304E5AQ38029304-41842CCA-B7EF-484D-A80D-E0D083104A10Q38062785-9A860EAA-4998-4A70-A8C8-F563B28E3402Q38142887-AB8132EB-DC24-49E3-8F90-AC4BA04B0FCEQ38221786-D60E9A99-75C4-4646-BFE6-0455EEE12665
P2860
Post-translational modifications differentially affect IgG1 conformation and receptor binding.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Post-translational modificatio ...... ormation and receptor binding.
@ast
Post-translational modificatio ...... ormation and receptor binding.
@en
type
label
Post-translational modificatio ...... ormation and receptor binding.
@ast
Post-translational modificatio ...... ormation and receptor binding.
@en
prefLabel
Post-translational modificatio ...... ormation and receptor binding.
@ast
Post-translational modificatio ...... ormation and receptor binding.
@en
P2093
P2860
P1476
Post-translational modificatio ...... ormation and receptor binding.
@en
P2093
Damian Houde
Steven A Berkowitz
Yucai Peng
P2860
P304
P356
10.1074/MCP.M900540-MCP200
P577
2010-01-26T00:00:00Z